Drug intelligence / Profile preview

EPS-WB4503

Development stage: Preclinical
Administration: Oral

Overview

EPS-WB4503 is a crude exopolysaccharide (EPS) produced by the probiotic bacterium *Lactiplantibacillus plantarum* WB4503, which was isolated from kimchi. Research indicates that EPS-WB4503 possesses significant anticancer properties, specifically targeting human colorectal cancer cells (HT-29). It functions by inducing the intrinsic apoptosis pathway, evidenced by the activation of caspase-3 and caspase-9, and an increase in the Bax/Bcl-2 ratio, leading to DNA fragmentation and reduced cell viability. It is being explored as a potential bioactive component for functional foods and nutraceutical applications in cancer prevention.

Other names: Exopolysaccharide of Lactiplantibacillus plantarum WB4503WB4503 EPSWB-4503 EPSWB 4503 EPS

Targets

CASP9 (Caspase-9)BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)

Beyond the preview

Go deeper on EPS-WB4503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPS-WB4503.

Explore the full profile